Navigation Links
Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
Date:8/31/2009

MONT-SAINT-GUIBERT, Belgium, August 31 /PRNewswire/ --

- Symposium Session Draws Leading Experts to Review Recent Developments in Cardiac Regenerative Therapies

Cardio3 BioSciences, today provided an update and review of the clinical development of its unique C-Cure(R) therapy at the European Society of Cardiology Congress in Barcelona. A unique second generation stem-cell derived therapy, C-Cure allows the differentiation of a patient's own cells into 'cardiopoietic' cells which grow into new heart cells and repair heart muscle. C-Cure is currently undergoing a randomized, multi-center pivotal trial, designed to evaluate the safety and efficacy beyond optimal clinical care in patients with heart failure, one of the world's largest unmet medical needs.

The update was part of a broader satellite symposium at the Congress led by a panel of expert speakers. In addition to reviewing C-Cure the distinguished panel traced the progress made in the development of regenerative therapies for heart failure from first generation to second generation products.

The session was led by Prof. Stephanie Dimmeler (Institute for Cardiovascular Regeneration, Goethe University Frankfurt) and Prof. Michael Tendera (Head, Cardiology Division, Medical University of Silesia, Katowice, Poland) and included cardiology experts from leading European and U.S institutions: Dr Josef Bartunek (Cardiovascular Center Aalst, Belgium), Professors Dominique Charron (St Louis Hospital, Paris, France), Helmut Drexler (Hannover Medical school, Germany), Andre Terzic (Mayo Clinic, Rochester U.S.A) and Catherine Verfaillie (Leuven University, Belgium).

Dr Christian Homsy, CEO of Cardio3 BioSciences said: "The potential of cell therapies for the treatment of heart failure has long been recognised but there have been considerable hurdles to overcome in delivering on the promise. Today's expert pane
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
(Date:3/3/2015)... 3, 2015 Fried, Frank, Harris, Shriver & ... has joined the Firm as a partner in ... New York office. Mr. Lewis concentrates ... well as other intellectual property and general litigation. A ... represents both plaintiffs and defendants in a range of ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... first quarter 2008 stock ... repurchase program, BOSTON, April 30 ... image and information management,solutions, today reported unaudited financial results for the first ... ), Q1 Financial Highlights, Revenue: Total revenues for the ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a ... financial results for Q1 2008. Q1 2008,revenues were ... 2007., Q1 2008 revenues increased 5% in ... in its vascular category, while general,surgery revenues decreased ...
... New Step in the Company,s Global Branding Strategy, ... today announced the full integration of its Riedel-de ... May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We have ... and,services," said Josef Zihlmann, Global Vice President of ...
Cached Biology Technology:AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... extend a family should avoid using the cholesterol-lowering drugs ... that women who are pregnant should stop taking statins ... cholesterol is essential for normal fetal development. Indeed, ... in children of pregnant women using statins suggested that ...
... for HIV patients may be the best way of treating hepatitis ... A study of a protein called p7, has revealed that differences ... - known as genotypes - alter the sensitivity of the ... protein assists the spread of HCV around the body ...
... researchers from Penn State University and the University of Chicago ... particular virus, called N4, injects an unusual substance -- an ... bacterial cell. The results, which are published in the ... to improved understanding of the infection strategies used by viruses ...
Cached Biology News:Statin warning for pregnant women 2Leeds research points to new therapy for hepatitis C treatment 2Properties of unusual virus revealed in research 2Properties of unusual virus revealed in research 3
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
...
Biology Products: